Formulations comprising glucagon
US9334316B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 9, 2015 |
| Grant date | May 10, 2016 |
| Priority date | — |
| Expiry date | Apr 9, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Glucagon formulations that resist fibril formation are disclosed. The formulations comprise curcumin derivatives such as ferulic acid and/or tetrahydrocurcumin and can further comprise human serum albumin, polysorbate-80, and L-methionine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.